Stents Market - Global Forecast 2025-2032

The stents market is advancing steadily as healthcare systems worldwide rely on innovative interventional devices to deliver minimally invasive therapies, improve patient outcomes, and support evolving clinical protocols.

Market Snapshot: Global Stents Market Growth

The global stents market grew from USD 13.95 billion in 2024 to USD 15.01 billion in 2025, and is projected to expand at a CAGR of 7.73%, reaching USD 25.33 billion by 2032. Adoption is accelerating due to the rising burden of cardiovascular and chronic diseases, growing preference for minimally invasive solutions, and rapid material innovation. The market benefits from increased investments in R&D, advances in smart technologies, and collaborative regulatory landscapes, offering significant opportunities for device manufacturers and healthcare providers.

Scope & Segmentation

This report delivers a comprehensive analysis across product categories, materials, clinical channels, and global geographies, offering insights designed for strategy and procurement decision-making.

• Product Types: Coronary stents, gastrointestinal stents, neurovascular stents (extracranial carotid artery stents, intracranial stents), peripheral stents (carotid, femoral, iliac, renal artery stents), urological stents (prostatic, ureteral stents)
• Materials: Metallic stents (cobalt chromium, nitinol, platinum chromium, stainless steel), polymeric stents (biodegradable, non-biodegradable polymers)
• Delivery Modes: Balloon-expandable stents, self-expanding stents
• Clinical Applications: Cardiovascular diseases, gastrointestinal obstructions, neurovascular conditions, oncology-related uses, peripheral artery disease, urological disorders
• End User Channels: Ambulatory surgical centers, cardiology centers, hospitals, specialty clinics
• Regions Covered: Americas (North America, Latin America), Europe, Middle East, Africa, Asia-Pacific
• Companies Analyzed: Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, B. Braun Melsungen AG, Biotronik SE & Co. KG, Cook Medical LLC, MicroPort Scientific Corporation, Lepu Medical Technology Co., Ltd., Cordis Corporation

Key Takeaways for Senior Decision-Makers

• Stent technology advancements—from drug-eluting coatings to biodegradable materials—are transforming clinical practice, reducing complications, and meeting the needs of high-risk patients.
• Integration of digital features such as embedded sensors is enabling real-time monitoring and predictive therapy management, enhancing value-based healthcare delivery.
• Tariff changes in major markets have impacted raw material costs and disrupted supply chains, prompting companies to adopt nearshoring and diversify sourcing and manufacturing partnerships.
• Personalized device customization through 3D printing and smart system integration is expanding the addressable market and supporting tailored patient care.
• Regulatory collaboration and harmonization are streamlining approval processes, giving faster access to breakthrough devices and encouraging global innovation diffusion.
• Efforts to optimize environmental sustainability in stent production and supply are strengthening compliance with emerging ESG benchmarks.

Assessing the Impact of US Tariff Policy on Stent Market Supply and Trade

Recent shifts in United States tariff policy have led to higher costs for critical raw materials such as stainless steel and specialized alloys, challenging device manufacturers and their value chains. In response, industry leaders are moving toward domestic sourcing, strengthening supplier agreements, and building inventory resilience. These efforts are complemented by engagement with trade authorities to secure favorable exemptions and adapt classification frameworks for medical devices.

Research Methodology & Data Sources

The report’s insights stem from robust primary and secondary research, including deep-dives into scientific literature, regulatory filings, and market disclosures. Interviews with clinical and operational stakeholders, combined with expert panel reviews, ensure rigorous data triangulation and scenario modeling for actionable analysis.

Why This Report Matters

• Enables procurement and R&D leaders to track market-shaping innovation and adapt product portfolios to fast-evolving clinical needs.
• Provides a global view of competitive moves, regulatory trends, and supply chain adaptations necessary for resilient growth.
• Guides strategic planning for entry, expansion, and compliance across diverse regional healthcare environments.

Conclusion

This report equips senior leaders with the strategic insights needed to drive innovation, improve clinical value, and fortify operational resilience amid growing complexities in the global stents market.